Celanese (CE)
(Delayed Data from NYSE)
$156.53 USD
-0.81 (-0.51%)
Updated May 20, 2024 04:00 PM ET
After-Market: $156.51 -0.02 (-0.01%) 7:30 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$156.53 USD
-0.81 (-0.51%)
Updated May 20, 2024 04:00 PM ET
After-Market: $156.51 -0.02 (-0.01%) 7:30 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
Zacks News
Celanese (CE) Gains on Acquisitions & Productivity Actions
by Zacks Equity Research
While Celanese (CE) faces headwinds from weaker demand and destocking, it benefits from productivity measures, investments in organic projects and strategic acquisitions.
Celanese (CE) Up 15% in 3 Months: What's Driving the Stock?
by Zacks Equity Research
Celanese (CE) benefits from productivity measures, investments in organic projects and strategic acquisitions.
Why Is Celanese (CE) Up 14.4% Since Last Earnings Report?
by Zacks Equity Research
Celanese (CE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Celanese (CE) in Your Portfolio
by Zacks Equity Research
Celanese (CE) gains on productivity actions, investments in high-return organic projects and synergies of acquisitions.
Celanese's (CE) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Celanese (CE) witnesses increased volumes due to an additional month of sales from the Mobility & Materials acquisition as well as demand recovery in Europe and Asia in Q1.
Celanese (CE) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Celanese (CE) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Celanese (CE) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Celanese (CE) delivered earnings and revenue surprises of 21.08% and 4.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Stocks Enter Sixth Week of Low Volatility as Earnings Beat Expectations
by Mayur Thaker
April jobs beat expectations, but primary economic trends remain bearish.
Celanese (CE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Celanese (CE) is likely to have gained from pricing and productivity actions amid headwinds from higher input costs and destocking in Q1.
DOW Selects Linde for Ethylene Cracker and Derivatives Site
by Zacks Equity Research
The ethylene cracker and derivatives complex will decarbonize roughly 20% of Dow's (DOW) global ethylene capacity while increasing its global polyethylene supply by around 15%.
Air Products (APD) to Build Hydrogen Refueling Station in Alberta
by Zacks Equity Research
The hydrogen refueling station will be Air Products' (APD) first in Canada. It will also be Alberta's first commercial-scale hydrogen refueling station.
Celanese (CE) Up 24% in 6 Months: What's Driving the Stock?
by Zacks Equity Research
Celanese (CE) gains on cost and productivity actions, investments in high-return projects and contributions of acquisitions.
Celanese (CE) & Glaukos Join Forces for Glaucoma Treatment
by Zacks Equity Research
Celanese (CE) partners with Glaukos to provide VitalDose for sustained release treatment for glaucoma.
Is Invesco S&P 500 Equal Weight Materials ETF (RTM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RTM
Is First Trust Large Cap Value AlphaDEX ETF (FTA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTA
Here's Why You Should Retain Celanese (CE) in Your Portfolio
by Zacks Equity Research
Celanese (CE) gains on productivity actions, investments in high-return organic projects and synergies of acquisitions.
Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FEX
Should You Invest in the Invesco S&P 500 Equal Weight Materials ETF (RTM)?
by Zacks Equity Research
Sector ETF report for RTM
Should First Trust Large Cap Core AlphaDEX ETF (FEX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FEX
Is First Trust Multi Cap Value AlphaDEX ETF (FAB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAB
Should First Trust Large Cap Value AlphaDEX ETF (FTA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTA
Celanese (CE) Partners With Alessa for Drug Delivery System
by Zacks Equity Research
Celanese (CE) forms an alliance with Alessa Therapeutics to develop an innovative drug delivery system for oncology patients.
Celanese (CE) & Mitsui Ink New Partnership, Extend Fairway JV
by Zacks Equity Research
Celanese (CE) joins forces with Mitsui to form a new Food Ingredient joint venture to strengthen its strategic partnership with the latter.
Celanese's (CE) Earnings and Revenues Miss Estimates in Q4
by Zacks Equity Research
Input cost inflation, supply chain disruptions and consumer destocking weigh on fourth-quarter performance of Celanese (CE).
Celanese (CE) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Celanese (CE) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.